Press Releases

MGEN $0.60 $ + 0.02 (3.10%)

Press Releases

Search Press Releases
  
Subscribe for Email Alerts
11/26/2019
8:00 AM ET
Press Release

miRagen to Present at the Evercore ISI HealthCONx Conference 2019

11/26/2019

BOULDER, Colo., Nov. 26, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific...

 Continue Reading
11/7/2019
4:01 PM ET
Earnings Release

miRagen Reports Third Quarter 2019 Results and Provides Corporate Update

11/7/2019

Announced positive data from two Phase 1 clinical trials of MRG-110Remain on track to announce interim top-line data from its Phase 2 clinical trial of remlarsen in keloids by year endImplemented rest...

 Continue Reading
10/28/2019
9:00 AM ET
Press Release

miRagen to Present at the DIA/FDA Oligonucleotide-Based Therapeutics Conference Today

10/28/2019

An overview of its second-generation miR-29 mimicsClinical development of its microRNA inhibitors BOULDER, Colo., Oct. 28, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clini...

 Continue Reading
10/22/2019
8:00 AM ET
Press Release

miRagen Therapeutics to Report Third Quarter 2019 Financial Results and Host a Conference Call

10/22/2019

BOULDER, Colo., Oct. 22, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific...

 Continue Reading
10/16/2019
2:45 AM ET
Press Release

miRagen Announces New Clinical Data Showing MRG-110 Positively Impacted Tissue Repair and New Blood Vessel Growth

10/16/2019

Data included in an oral presentation at the 15th annual meeting of the Oligonucleotide Therapeutics Society

Data supports advancing MRG-110 into additional clinical studies

BOU...

 Continue Reading
Displaying 1 to 5 (of 87 releases)